Antibody-drug conjugate news and latest updates

News and Trends 14 Jun 2017

Understand your Biologics: De-Risking the Biotech Pipeline

Characterizing biologics has become an essential step for successful drug development. We connected with SCIEX to learn how to tackle the biggest challenges. Biologics are taking over the market. Some of the top-selling drugs worldwide are antibodies and recombinant proteins, and new technologies such as Antibody-Drug Conjugates (ADCs) are on track to revolutionize the extremely […]

June 14, 2017 - 5 minutesmins - By External Contributor

News and Trends 1 Jun 2017

Next-Gen Drug Conjugates Bank €46M in Series B with American Investors

Bicycle Therapeutics has closed a massive fundraising round, raking in £40M (€46M) from American investors to launch clinical trials. Bicycle Therapeutics, the most recent company founded by the legendary academic-entrepreneur Greg Winter, is making a name for itself as a money magnet. Hot on the heels of a €1B deal with AstraZeneca last fall, the biotech […]

June 1, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 24 Feb 2017

What are the Current Challenges in the Booming Field of ADCs?

ADCs are overcoming the challenges of first generations and returning with a vengeance. I attended the World ADC Conference to hear about current efforts. ADCs represent an exciting new field that has seen renewed interest in the past few months, as funding has poured into NBE Therapeutics and ADC Therapeutics. Theses drugs are overcoming the challenges that held the first two generations back […]

February 24, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 23 Feb 2017

In the Age of Biological Therapeutics, Chemists move to ADCs

Career options for chemists are shrinking in the shift towards biological drugs. But as antibody-drug conjugates (ADCs) take off, so do opportunities for chemists! Since I quit graduate school in chemistry research and dove into biotech journalism, I wasn’t sure when I would next enter a discussion about organic synthesis. This week, less than a year after […]

February 23, 2017 - 4 minutesmins - By Evelyn Warner

Best in Biotech 3 Jan 2017

10 Hot European Biotechs to Observe in 2017 🚀

New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in no particular order. Super-pumped mRNA Therapy BioNTech is Europe’s largest private Biotech with over 500 employees and is one of the three leading mRNA therapy […]

January 3, 2017 - 5 minutesmins - By Philip Hemme

News and Trends 7 Dec 2016

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

Nordic Nanovector has bagged €55M to push its pipeline forward through the clinic. Investors seem to be attracted by its ARC and ADC programs, using some of the hottest antibody technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These […]

December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Dec 2016

Another Pharma sloughs off Small Molecules to focus on Biologics

BI has taken an axe to its small molecule discovery program in order to focus on immuno-oncology in the latest farewell to old-school chemical drugs. Over 90% of the drugs on the market today are small molecules, but the bell has been tolling for these therapies for some time now as biopharma is increasingly focused […]

December 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 2 Dec 2016

Better than ADCs? AstraZeneca bids for Bicyclic Peptides

AstraZeneca has signed a deal with Bicycle Therapeutics that could exceed €1B. The foundation is bicyclic peptides, which combine the best of antibodies and small molecules. Could Bicycle Drug Conjugates (BDCs) outperform ADCs? Bicycle Therapeutics is a company in Cambridge founded by one of the top biotech leaders in the UK’s golden triangle. Its unique technology […]

December 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer

PharmaMar announced positive preclinical results for an ADC candidate, showing that the traditional chemistry-based pharma companies are shifting towards the new generation of biologicals. PharmaMar is an oncology pharma in Madrid mining a vast source for drug discovery: marine organisms. The company is now pivoting to a more innovative technology with the announcement of positive […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 29 Nov 2016

The ABCs of ADCs: A Review of Antibody Drug Conjugates

Antibody therapies have a little sister who is catching up in funding – and hype? In light of now five deaths from Juno’s CAR-T therapy, antibody drug conjugates are attracting a lot of interest in a resurgence after their debut 10 years ago. To feel out the field, we talked to two CEOs competing directly […]

November 29, 2016 - 8 minutesmins - By Evelyn Warner

News and Trends 26 Oct 2016

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat Non-Hodgkin Lymphoma (NHL) and other blood cancers. Today, the company has announced a collaboration with Wilex’ subsidiary Heidelberg Pharma to incorporate antibody-drug conjugates (ADCs) […]

October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2016

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

AstraZeneca has contributed to ADC Therapeutics’ €96M fundraising, the biggest round so far in Europe this year. Will this huge investment pay out for the British-Swedish Big Pharma? ADC Therapeutics (ADCT) is a Swiss Biotech that develops antibody-drug conjugates (ADCs) for oncology applications. Its founder Auven Therapeutics and its partner AstraZeneca have participated in the biggest […]

October 19, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Antibody-drug conjugates

Understand your Biologics: De-Risking the Biotech Pipeline

Next-Gen Drug Conjugates Bank €46M in Series B with American Investors

What are the Current Challenges in the Booming Field of ADCs?

In the Age of Biological Therapeutics, Chemists move to ADCs

10 Hot European Biotechs to Observe in 2017 🚀

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

Another Pharma sloughs off Small Molecules to focus on Biologics

Better than ADCs? AstraZeneca bids for Bicyclic Peptides

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer

The ABCs of ADCs: A Review of Antibody Drug Conjugates

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!